Results 11 to 20 of about 519,424 (350)
Frontiers in Oncology, 2021 Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis.
Ting-Ting Yang +17 more
doaj +1 more source
Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. [PDF]
, 2017 BackgroundLiposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease.
Doan, Ngan B +9 more
core +2 more sources
Current Problems in Cancer: Case Reports, 2021 Patients with metastatic renal cell carcinoma are often affected by metastases to the brain that result in significant complications as well as limitations in clinical trial participation.
Cierra Hong +5 more
doaj +1 more source
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]
, 2014 Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani +59 more
core +1 more source
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease
Molecules, 2020 In recent years, multitarget drugs for neurological diseases such as Alzheimer’s disease have been developed and well researched. Many studies have revealed that multitarget drugs are also useful for lung cancer and respiratory diseases.
Masako Yumura +2 more
doaj +1 more source
TYROSINE KINASE INHIBITORS AND INTERFERON
Mediterranean Journal of Hematology and Infectious Diseases, 2014 The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for Chronic Myeloid Leukemia (CML) patients unfit for bone marrow transplantation. With the appearance
Dimou, M., Panayiotidis, P.
openaire +4 more sources
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy
Haematologica, 2011 Background Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia.
Benjamin Hanfstein +9 more
doaj +1 more source
TYROSINE KINASE INHIBITORS AND PREGNANCY
Mediterranean Journal of Hematology and Infectious Diseases, 2014 The management of patients with chronic myeloid leukemia (CML) during pregnancy has became recently a matter of continuous debate. The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of CML patients.
Elisabetta Abruzzese +3 more
openaire +4 more sources
Nilotinib-Associated Destructive Thyroiditis
Case Reports in Endocrinology, 2015 Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia.
Suhalia Bakerywala +4 more
doaj +1 more source
A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. [PDF]
, 2016 The MST1R gene is overexpressed in pancreatic cancer producing elevated levels of the RON tyrosine kinase receptor protein. While mutations in MST1R are rare, alternative splice variants have been previously reported in epithelial cancers.
Babicky, M +10 more
core +2 more sources